These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7333261)

  • 1. Epidemiological studies for regulatory agencies.
    Hunt VR
    Environ Health Perspect; 1981 Dec; 42():61-5. PubMed ID: 7333261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When are studies adequate for regulatory purposes? View of one regulated.
    Bundy M
    Environ Health Perspect; 1981 Dec; 42():67-72. PubMed ID: 7333262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary: the Interagency Regulatory Liaison Group "Guidelines for Documentation of Epidemiologic Studies". Joint Committee on Governmental Affairs of the Epidemiology Section (American Public Health Association) and the Society for Epidemiologic Research.
    Am J Epidemiol; 1981 Nov; 114(5):614-8. PubMed ID: 7304594
    [No Abstract]   [Full Text] [Related]  

  • 4. Guidelines for documentation of epidemiologic studies. Epidemiology Work Group of the Interagency Regulatory Liaison Group.
    Am J Epidemiol; 1981 Nov; 114(5):609-13. PubMed ID: 7304593
    [No Abstract]   [Full Text] [Related]  

  • 5. Legislative aspects of hazardous waste management.
    Friedman M
    Environ Health Perspect; 1983 Feb; 48():19-23. PubMed ID: 6825630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lead: a case study in interagency policy-making.
    Billick IH
    Environ Health Perspect; 1981 Dec; 42():73-9. PubMed ID: 7333263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ICCVAM evaluation of the murine local lymph node assay. The ICCVAM review process.
    Sailstad DM; Hattan D; Hill RN; Stokes WS
    Regul Toxicol Pharmacol; 2001 Dec; 34(3):249-57. PubMed ID: 11754529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FIFRA Scientific Advisory Panel as a model for peer review of scientific regulatory decisions.
    Neal RA
    Fundam Appl Toxicol; 1982; 2(6):276-7. PubMed ID: 7185625
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification, characterization, and control of potential human carcinogens: a framework for Federal decision-making.
    Calkins DR; Dixon RL; Gerber CR; Zarin D; Omenn GS
    J Natl Cancer Inst; 1980 Jan; 64(1):169-76. PubMed ID: 6928042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interagency Regulatory Liaison Group role in phthalates.
    Johns PA
    Environ Health Perspect; 1982 Nov; 45():145-7. PubMed ID: 7140690
    [No Abstract]   [Full Text] [Related]  

  • 12. The calculation and use of carcinogenic potency: a review.
    Barr JT
    Regul Toxicol Pharmacol; 1985 Dec; 5(4):432-59. PubMed ID: 3912853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in dietary exposure research at the United States Environmental Protection Agency-National Exposure Research Laboratory.
    Berry MR
    J Expo Anal Environ Epidemiol; 1997; 7(1):3-16. PubMed ID: 9076607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical mixtures: considering the evolution of toxicology and chemical assessment.
    Monosson E
    Environ Health Perspect; 2005 Apr; 113(4):383-90. PubMed ID: 15811826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPA, environmental release, and the regulatory process.
    Farnham P
    FASEB J; 1989 Apr; 3(6):1687-8. PubMed ID: 2703105
    [No Abstract]   [Full Text] [Related]  

  • 16. Approaches for exposure characterization and data needs for hazardous waste site assessment.
    Waldman JM
    Environ Health Perspect; 1995 Feb; 103 Suppl 1(Suppl 1):99-104. PubMed ID: 7621812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of benefit-cost analysis in the regulatory process at EPA.
    Luken RA
    Environ Health Perspect; 1985 Oct; 62():373-9. PubMed ID: 3936707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on the place of environmental health and protection in public health and public health agencies.
    Kotchian S
    Annu Rev Public Health; 1997; 18():245-59. PubMed ID: 9143719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk.
    Kavlock R; Dix D
    J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):197-217. PubMed ID: 20574897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety assessment programs for U.S. regulatory agencies: a perspective of requirements and compliance.
    Bendele RA
    Toxicol Pathol; 1994; 22(2):95-104. PubMed ID: 7973375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.